MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025

Reuters

Oct 20

MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025

MetaVia Inc., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01238) on October 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576517338"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576517338\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576517338?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576517338","market":"nz","top_or_hot":-1,"title":"MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01238) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01238) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL8PNqyk:1","article_id":"2576517338","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576517338","pubTimestamp":1760963488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MetaVia Inc., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor  and glucagon receptor . The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MTVA":"MetaVia Inc"},"translate_title":"MetaVia在2025年肥胖周上展示了有希望的DA-1726 1期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTVA":0.9},"content_text":"MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025\n    \n\nMetaVia Inc., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01238) on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}